The world’s first cannabinoid-based antitumor Drug Candidate for the treatment of Colorectal Cancer based on our novel and proprietary formulation CNBX RCC-33
Proud to be a global leader in the development
of cancer & cancer related cannabinoid-molecule based therapeutic
formulations and medicines
CNBX Pharmaceuticals has been
conducting research on the antitumor effects of
cannabinoid formulations on cancer since its
establishment in 2012.
CNBX Pharmaceuticals’ groundbreaking research and development is carried out in our in-house state of the art drug discovery facilities using proprietary High Throughput Screening (HTS) technology and advanced bioinformatics.